FDA Drugs Field Staff May Be Based In Four Offices After Realignment
This article was originally published in The Tan Sheet
Pharmaceutical-focused field offices are another result of FDA’s Program Alignment Group process.
You may also be interested in...
In updated high-risk report, GAO says resources are an issue for FDA’s globalization plans and the agency should better manage its drug shortage data.
President Obama’s FY 2016 blueprint includes cuts to ‘low-priority’ enforcement, surveillance and other activities in FDA human drugs and biologics programs, but still increases those operations overall.
Commissioner Hamburg asks for more power over non-traditional compounding to better regulate companies like the New England Compounding Center, but several House members say it looks like the agency already has the authority it needs.